Metropolis Healthcare Limited has informed the Exchange about Transcript

Metropolis Healthcare reported Q1 FY26 group revenue growth of 23%, driven by 13.2% organic growth and contributions from recently acquired entities (Core Diagnostics, DAPIC Dehradun, Scientific Pathology Agra). Organic EBITDA margin stood at 24.7%, up 40 basis points sequentially, with PAT up 21.2% YoY at Rs 46.2 crores. B2C revenue grew 16% and B2B grew 10% organically, with TruHealth preventive portfolio contributing 18% of revenue (growing 22%). The company added 80 new collection centers in Q1 and is targeting 400+ additions this year, expanding from 750 to 1,000 towns. Management announced a new acquisition of Ambika Diagnostics in Kolhapur for Rs 17 crores (Rs 8 crores revenue, Rs 3.4 crores post-synergy EBITDA), and Core Diagnostics turned positive at low single-digit margin with a target of high single-digit by year-end. Core's Rs 12 crore loan was refinanced in July at a better rate.